The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer
This study aimed to analyze the prognostic significance of the positive nodal chain ratio (NCR) in non-small-cell lung cancer (NSCLC). A total of 208 pIIIa-N2 NSCLC patients who underwent complete surgical resections with a systematic nodal dissection were enrolled. The median values of NCR and the...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2015-06, Vol.36 (6), p.4617-4625 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4625 |
|---|---|
| container_issue | 6 |
| container_start_page | 4617 |
| container_title | Tumor biology |
| container_volume | 36 |
| creator | Cao, Qinchen Zhang, Baozhong Zhao, Lujun Wang, Changli Gong, Liqun Wang, Jun Pang, Qingsong Li, Kai Liu, Weishuai Li, Xue Wang, Peng Wang, Ping |
| description | This study aimed to analyze the prognostic significance of the positive nodal chain ratio (NCR) in non-small-cell lung cancer (NSCLC). A total of 208 pIIIa-N2 NSCLC patients who underwent complete surgical resections with a systematic nodal dissection were enrolled. The median values of NCR and the positive lymph node ratio (LNR) were used to grouping patients. The differences of overall survival (OS) and disease-free survival (DFS) between the different groups were compared. The median values of NCR and LNR were 0.31 and 0.45, respectively. The patients were separated into group A (NCR ≤0.45 and LNR ≤0.31; 91 cases), group B (NCR ≤0.45 and LNR >0.31 or NCR >0.45 and LNR ≤0.31; 51 cases), and group C (NCR >0.45 and LNR >0.31; 66 cases) according to their combined LCR and LNR values. Groups A, B, and C exhibited significantly different prognoses (5-year OS: 43.7, 25.2, and 12.3 %, respectively,
p
0.31. NCR combined with LNR may be more effective to guide individualized multimodality therapy including postoperative chemoradiotherapy for pIIIa-N2 NSCLC. |
| doi_str_mv | 10.1007/s13277-015-3109-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1702651809</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3771765171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-80a0ef90fe68b3601b2f4f3804cfb962b37fb7c537ea3c6f875c3be9c68592a93</originalsourceid><addsrcrecordid>eNp1kU2P1SAYhYnROB_6A9wYEjdu0BdoCyzNxK9kEjfjmlAKc5lQqNBOcufXS72jMSaueBOec96Pg9ArCu8ogHhfKWdCEKA94RQUkU_QOe0YJ8AlPG01UCAdk_wMXdR6Bw1UaniOzlg_ME5pf47SzcHhMC_Grjh7vOQa1nDvcMqTidgeTEi4mDVknBMOaQr3YdpMDA9uwvMW1zDvYFiPeD24YpZjg5o4kTqbGIl1MeK4pVtsTbKuvEDPvInVvXx8L9H3Tx9vrr6Q62-fv159uCaWq24lEgw4r8C7QY58ADoy3_m2VGf9qAY2cuFHYXsunOF28FL0lo9O2UH2ihnFL9Hbk-9S8o_N1VXPoe7DmOTyVjUVwIaeStjRN_-gd3krqU33i2IURC8bRU-ULbnW4rxeSphNOWoKeg9Dn8LQ7cZ6D0PvmtePzts4u-mP4vf1G8BOQG1f6daVv1r_1_UnKbGVSw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1702210758</pqid></control><display><type>article</type><title>The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Cao, Qinchen ; Zhang, Baozhong ; Zhao, Lujun ; Wang, Changli ; Gong, Liqun ; Wang, Jun ; Pang, Qingsong ; Li, Kai ; Liu, Weishuai ; Li, Xue ; Wang, Peng ; Wang, Ping</creator><creatorcontrib>Cao, Qinchen ; Zhang, Baozhong ; Zhao, Lujun ; Wang, Changli ; Gong, Liqun ; Wang, Jun ; Pang, Qingsong ; Li, Kai ; Liu, Weishuai ; Li, Xue ; Wang, Peng ; Wang, Ping</creatorcontrib><description>This study aimed to analyze the prognostic significance of the positive nodal chain ratio (NCR) in non-small-cell lung cancer (NSCLC). A total of 208 pIIIa-N2 NSCLC patients who underwent complete surgical resections with a systematic nodal dissection were enrolled. The median values of NCR and the positive lymph node ratio (LNR) were used to grouping patients. The differences of overall survival (OS) and disease-free survival (DFS) between the different groups were compared. The median values of NCR and LNR were 0.31 and 0.45, respectively. The patients were separated into group A (NCR ≤0.45 and LNR ≤0.31; 91 cases), group B (NCR ≤0.45 and LNR >0.31 or NCR >0.45 and LNR ≤0.31; 51 cases), and group C (NCR >0.45 and LNR >0.31; 66 cases) according to their combined LCR and LNR values. Groups A, B, and C exhibited significantly different prognoses (5-year OS: 43.7, 25.2, and 12.3 %, respectively,
p
< 0.0001; 5-year DFS: 30.4, 23.3, and 8.6 %, respectively,
p
< 0.0001). Multivariate analyses revealed that this novel grouping method based on the combination of NCR and LNR was an independent prognostic factor for 5-year OS and 5-year DFS in pIIIa-N2 NSCLC. In group C, patients who received no postoperative treatment, adjuvant chemotherapy alone, or chemoradiotherapy exhibited different 5-year OS rates (0.0, 11.6, and 37.5 %, respectively,
p
= 0.003) and 5-year DFS rates (0.0, 7.5, and 25.0 %, respectively,
p
= 0.009). Therefore, postoperative chemoradiotherapy may significantly improve the prognosis of patients displaying NCR >0.45 and LNR >0.31. NCR combined with LNR may be more effective to guide individualized multimodality therapy including postoperative chemoradiotherapy for pIIIa-N2 NSCLC.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-015-3109-8</identifier><identifier>PMID: 25623115</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adult ; Aged ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - surgery ; Chemotherapy ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Humans ; Lung cancer ; Lymph Nodes - pathology ; Lymph Nodes - surgery ; Lymphatic Metastasis ; Lymphatic system ; Male ; Medical prognosis ; Middle Aged ; Neoplasm Staging ; Positron-Emission Tomography ; Prognosis ; Research Article</subject><ispartof>Tumor biology, 2015-06, Vol.36 (6), p.4617-4625</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c394t-80a0ef90fe68b3601b2f4f3804cfb962b37fb7c537ea3c6f875c3be9c68592a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13277-015-3109-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13277-015-3109-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25623115$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, Qinchen</creatorcontrib><creatorcontrib>Zhang, Baozhong</creatorcontrib><creatorcontrib>Zhao, Lujun</creatorcontrib><creatorcontrib>Wang, Changli</creatorcontrib><creatorcontrib>Gong, Liqun</creatorcontrib><creatorcontrib>Wang, Jun</creatorcontrib><creatorcontrib>Pang, Qingsong</creatorcontrib><creatorcontrib>Li, Kai</creatorcontrib><creatorcontrib>Liu, Weishuai</creatorcontrib><creatorcontrib>Li, Xue</creatorcontrib><creatorcontrib>Wang, Peng</creatorcontrib><creatorcontrib>Wang, Ping</creatorcontrib><title>The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>This study aimed to analyze the prognostic significance of the positive nodal chain ratio (NCR) in non-small-cell lung cancer (NSCLC). A total of 208 pIIIa-N2 NSCLC patients who underwent complete surgical resections with a systematic nodal dissection were enrolled. The median values of NCR and the positive lymph node ratio (LNR) were used to grouping patients. The differences of overall survival (OS) and disease-free survival (DFS) between the different groups were compared. The median values of NCR and LNR were 0.31 and 0.45, respectively. The patients were separated into group A (NCR ≤0.45 and LNR ≤0.31; 91 cases), group B (NCR ≤0.45 and LNR >0.31 or NCR >0.45 and LNR ≤0.31; 51 cases), and group C (NCR >0.45 and LNR >0.31; 66 cases) according to their combined LCR and LNR values. Groups A, B, and C exhibited significantly different prognoses (5-year OS: 43.7, 25.2, and 12.3 %, respectively,
p
< 0.0001; 5-year DFS: 30.4, 23.3, and 8.6 %, respectively,
p
< 0.0001). Multivariate analyses revealed that this novel grouping method based on the combination of NCR and LNR was an independent prognostic factor for 5-year OS and 5-year DFS in pIIIa-N2 NSCLC. In group C, patients who received no postoperative treatment, adjuvant chemotherapy alone, or chemoradiotherapy exhibited different 5-year OS rates (0.0, 11.6, and 37.5 %, respectively,
p
= 0.003) and 5-year DFS rates (0.0, 7.5, and 25.0 %, respectively,
p
= 0.009). Therefore, postoperative chemoradiotherapy may significantly improve the prognosis of patients displaying NCR >0.45 and LNR >0.31. NCR combined with LNR may be more effective to guide individualized multimodality therapy including postoperative chemoradiotherapy for pIIIa-N2 NSCLC.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Combined Modality Therapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lymph Nodes - pathology</subject><subject>Lymph Nodes - surgery</subject><subject>Lymphatic Metastasis</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Positron-Emission Tomography</subject><subject>Prognosis</subject><subject>Research Article</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kU2P1SAYhYnROB_6A9wYEjdu0BdoCyzNxK9kEjfjmlAKc5lQqNBOcufXS72jMSaueBOec96Pg9ArCu8ogHhfKWdCEKA94RQUkU_QOe0YJ8AlPG01UCAdk_wMXdR6Bw1UaniOzlg_ME5pf47SzcHhMC_Grjh7vOQa1nDvcMqTidgeTEi4mDVknBMOaQr3YdpMDA9uwvMW1zDvYFiPeD24YpZjg5o4kTqbGIl1MeK4pVtsTbKuvEDPvInVvXx8L9H3Tx9vrr6Q62-fv159uCaWq24lEgw4r8C7QY58ADoy3_m2VGf9qAY2cuFHYXsunOF28FL0lo9O2UH2ihnFL9Hbk-9S8o_N1VXPoe7DmOTyVjUVwIaeStjRN_-gd3krqU33i2IURC8bRU-ULbnW4rxeSphNOWoKeg9Dn8LQ7cZ6D0PvmtePzts4u-mP4vf1G8BOQG1f6daVv1r_1_UnKbGVSw</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Cao, Qinchen</creator><creator>Zhang, Baozhong</creator><creator>Zhao, Lujun</creator><creator>Wang, Changli</creator><creator>Gong, Liqun</creator><creator>Wang, Jun</creator><creator>Pang, Qingsong</creator><creator>Li, Kai</creator><creator>Liu, Weishuai</creator><creator>Li, Xue</creator><creator>Wang, Peng</creator><creator>Wang, Ping</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150601</creationdate><title>The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer</title><author>Cao, Qinchen ; Zhang, Baozhong ; Zhao, Lujun ; Wang, Changli ; Gong, Liqun ; Wang, Jun ; Pang, Qingsong ; Li, Kai ; Liu, Weishuai ; Li, Xue ; Wang, Peng ; Wang, Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-80a0ef90fe68b3601b2f4f3804cfb962b37fb7c537ea3c6f875c3be9c68592a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Combined Modality Therapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lymph Nodes - pathology</topic><topic>Lymph Nodes - surgery</topic><topic>Lymphatic Metastasis</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Positron-Emission Tomography</topic><topic>Prognosis</topic><topic>Research Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Qinchen</creatorcontrib><creatorcontrib>Zhang, Baozhong</creatorcontrib><creatorcontrib>Zhao, Lujun</creatorcontrib><creatorcontrib>Wang, Changli</creatorcontrib><creatorcontrib>Gong, Liqun</creatorcontrib><creatorcontrib>Wang, Jun</creatorcontrib><creatorcontrib>Pang, Qingsong</creatorcontrib><creatorcontrib>Li, Kai</creatorcontrib><creatorcontrib>Liu, Weishuai</creatorcontrib><creatorcontrib>Li, Xue</creatorcontrib><creatorcontrib>Wang, Peng</creatorcontrib><creatorcontrib>Wang, Ping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Qinchen</au><au>Zhang, Baozhong</au><au>Zhao, Lujun</au><au>Wang, Changli</au><au>Gong, Liqun</au><au>Wang, Jun</au><au>Pang, Qingsong</au><au>Li, Kai</au><au>Liu, Weishuai</au><au>Li, Xue</au><au>Wang, Peng</au><au>Wang, Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>36</volume><issue>6</issue><spage>4617</spage><epage>4625</epage><pages>4617-4625</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>This study aimed to analyze the prognostic significance of the positive nodal chain ratio (NCR) in non-small-cell lung cancer (NSCLC). A total of 208 pIIIa-N2 NSCLC patients who underwent complete surgical resections with a systematic nodal dissection were enrolled. The median values of NCR and the positive lymph node ratio (LNR) were used to grouping patients. The differences of overall survival (OS) and disease-free survival (DFS) between the different groups were compared. The median values of NCR and LNR were 0.31 and 0.45, respectively. The patients were separated into group A (NCR ≤0.45 and LNR ≤0.31; 91 cases), group B (NCR ≤0.45 and LNR >0.31 or NCR >0.45 and LNR ≤0.31; 51 cases), and group C (NCR >0.45 and LNR >0.31; 66 cases) according to their combined LCR and LNR values. Groups A, B, and C exhibited significantly different prognoses (5-year OS: 43.7, 25.2, and 12.3 %, respectively,
p
< 0.0001; 5-year DFS: 30.4, 23.3, and 8.6 %, respectively,
p
< 0.0001). Multivariate analyses revealed that this novel grouping method based on the combination of NCR and LNR was an independent prognostic factor for 5-year OS and 5-year DFS in pIIIa-N2 NSCLC. In group C, patients who received no postoperative treatment, adjuvant chemotherapy alone, or chemoradiotherapy exhibited different 5-year OS rates (0.0, 11.6, and 37.5 %, respectively,
p
= 0.003) and 5-year DFS rates (0.0, 7.5, and 25.0 %, respectively,
p
= 0.009). Therefore, postoperative chemoradiotherapy may significantly improve the prognosis of patients displaying NCR >0.45 and LNR >0.31. NCR combined with LNR may be more effective to guide individualized multimodality therapy including postoperative chemoradiotherapy for pIIIa-N2 NSCLC.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>25623115</pmid><doi>10.1007/s13277-015-3109-8</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2015-06, Vol.36 (6), p.4617-4625 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1702651809 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy Chemotherapy, Adjuvant Combined Modality Therapy Disease-Free Survival Female Humans Lung cancer Lymph Nodes - pathology Lymph Nodes - surgery Lymphatic Metastasis Lymphatic system Male Medical prognosis Middle Aged Neoplasm Staging Positron-Emission Tomography Prognosis Research Article |
| title | The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T10%3A48%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20positive%20nodal%20chain%20ratio%20on%20individualized%20multimodality%20therapy%20in%20non-small-cell%20lung%20cancer&rft.jtitle=Tumor%20biology&rft.au=Cao,%20Qinchen&rft.date=2015-06-01&rft.volume=36&rft.issue=6&rft.spage=4617&rft.epage=4625&rft.pages=4617-4625&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-015-3109-8&rft_dat=%3Cproquest_cross%3E3771765171%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1702210758&rft_id=info:pmid/25623115&rfr_iscdi=true |